Nephrol Dial Transplant (2002) 17: 26-28
© 2002 European Renal Association-European Dialysis and Transplant Association
IV.5.3 Hyperlipidaemia
GuidelinesA. Hyperlipidaemia risk profiles should be identified by regular screening (at least once a year) for cholesterol, HDL-cholesterol, LDL-cholesterol and triglyceride blood levels in renal transplant patients.
(Evidence level B)
B. In renal transplant patients, hyperlipidaemia must be treated in order to keep the cholesterol/lipid levels within recommended limits according to the number of risk factors.
(Evidence level C)
C. Management of hyperlipidaemia after renal transplantation should be the same as for the dialysis population, with, in addition, modification of the immunosuppressive protocol when appropriate.
(Evidence level C)
D. Patients should be carefully monitored for adverse effects of lipid-lowering agents or interactions with immunosuppressive drugs.
(Evidence level B)
![]()
CiteULike
Connotea
Del.icio.us What's this?
This article has been cited by other articles:
![]() |
G. F M Strippoli, S. D Navaneethan, D. W Johnson, V. Perkovic, F. Pellegrini, A. Nicolucci, and J. C Craig Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ, March 22, 2008; 336(7645): 645 - 651. [Abstract] [Full Text] [PDF] |
||||
